The gene-therapy field spent a decade perfecting one virus. Carbon went looking for a whole different family - parvoviruses tuned by nature to carry more, target better, and maybe be given twice.
Carbon Biosciences is a preclinical genetic-medicine company in Waltham, Massachusetts, working on a question most of the gene-therapy industry stopped asking. For years, the standard delivery vehicle for a therapeutic gene has been the adeno-associated virus, or AAV - a small, well-studied capsid that carries a gene into the body's cells. AAV works, but it comes with limits: it can only hold a modest amount of genetic cargo, many people already carry antibodies against it, and once a patient is dosed, a second dose is often blocked by the immune system.
Rather than keep optimizing AAV, Carbon started somewhere else - the broader parvovirus family that AAV belongs to. These viruses, the company argues, have been "pressure tested by nature" to reach specific tissues and carry larger payloads, while attracting little pre-existing immunity. Carbon's proprietary vector engine, PAVE, mines and re-engineers that family into a new class of non-AAV capsids it calls CBN. The goal is a broader toolbox: vectors for tissues and diseases that current technology cannot reach, with the tantalizing possibility of re-dosing.
The company was created through Boston's Longwood Fund and launched publicly in June 2022 with a $38 million Series A. It is led by President and CEO Joel Schneider, and its science traces back to two gene-therapy pioneers who spent careers on parvoviruses while the rest of the field looked elsewhere.
"Carbon's platform has the potential to expand the role of gene therapy in treating some of the world's most devastating and difficult to treat diseases."
AAV set the ceiling for a generation of gene therapies. Carbon's pitch is that a different virus family raises it.
AAV maxes out near 4.7 kb - too small for many important genes. Carbon's CBN-1100 has demonstrated packaging of up to 5.9 kb, more than a kilobase of extra room.
Because the vectors draw on parvoviruses with minimal natural neutralizing immunity, Carbon believes patients may be treated more than once - a persistent weakness of AAV.
The CBN capsids have shown in-vivo tropism for hard-to-reach tissues like the lung airway and the heart, aiming genes where they are needed and away from the liver.
Carbon builds vectors with PAVE and points them at diseases where delivery has been the wall.
Carbon's discovery and engineering platform that mines the parvovirus family and produces the non-AAV "CBN" capsid class - the source of every program in the pipeline.
A human bocavirus-derived vector delivering the full-length CFTR gene to airway cells for cystic fibrosis. Given by nebulizer, it showed strong expression and tolerability in nonhuman primate lungs and functional correction in patient-derived cells.
A cardiac-targeting parvovirus vector with up to 5.9 kb capacity. Systemic dosing drove robust cardiomyocyte expression in rodents and primates, with a clean tolerability profile and low liver exposure.
"Preliminary pre-clinical data as well as studies on human populations suggest wide applicability of our lead clinical candidate and the potential to re-dose patients."
"Carbon's proprietary platform can address this challenge by leveraging novel vectors from the broader parvovirus family to deliver optimal payloads to specific tissues."
Carbon is a venture-backed, preclinical B2B biotech. Value is built in three places: proprietary vector IP, an in-house pipeline of drug candidates, and the option to partner or license with pharma. There is no commercial product yet - the beneficiaries are patients, and the near-term stakeholders are investors and disease foundations.
Carbon sits in the crowded gene-therapy delivery race, but from an unusual seat. Most rivals refine AAV; Carbon changes the virus entirely.
Notably, the Cystic Fibrosis Foundation - a disease nonprofit, not a generalist VC - joined the round, a signal that Carbon's lung program targets patients current CF drugs cannot help.
Carbon pairs deep academic parvovirus science with Longwood Fund's company-building model.
Longwood Fund-created Carbon emerges from stealth, led by Agent Capital, to advance a parvovirus vector platform aimed first at cystic fibrosis.
Carbon partners with WhiteLab Genomics to apply AI-driven design to viral-vector discovery and optimization.
The company presents four studies detailing CBN-1000 (CF) and CBN-1100 (cardiac) results plus manufacturing progress, and refreshes its board and scientific advisory board.
It develops gene therapies using non-AAV parvovirus vectors that can carry larger genetic payloads, target specific tissues, and provoke little pre-existing immunity - starting with cystic fibrosis.
Most companies optimize AAV. Carbon instead engineers vectors from the broader parvovirus family, including human bocavirus, aiming for bigger cargo capacity and the potential to re-dose patients.
CBN-1000 (program CGT-001), a bocavirus-derived vector delivering the full-length CFTR gene to the lung by nebulization; a second vector, CBN-1100, targets cardiac disease.
A $38M Series A in 2022 led by Agent Capital, with Longwood Fund, Astellas Venture Management, the Cystic Fibrosis Foundation, Solasta Ventures, UTokyoIPC and Camford Capital participating.
Waltham, Massachusetts. The company was created through Boston's Longwood Fund.
Note: the historical domain carbonbio.com is no longer operated by the company; use the LinkedIn and press links above for current information. Figures are drawn from public announcements and may be approximate.